JPRN-UMIN000008196已完成未知
Peg-IFN-alfa-2b/Ribavirin combination therapy for chronic hepatitis C patients: Effectiveness prediction by gene analysis and efficacy with Fluvastatin combination - Effectiveness prediction for Peg-IFN-alfa-2b/Ribavirin combination therapy for chronic hepatitis C and efficacy with Fluvastatin combination
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •contraindication of Peg-IFN/Ribavirin thrapy
研究者
相似试验
已完成
不适用
Peg-IFN-alfa2a/Ribavirin combination therapy for chronic hepatitis C with serogroup1 and high viral load: analysis of IL28B gene and efficacy of vitamin D combinatiochronic hepatitis CJPRN-UMIN000008197Kanazawa university200
已完成
不适用
PEG-IFN-alfa2b/Ribavirin combination therapy for chronic hepatitis C patients with low platelet count: efficacy and safetychronic hepatitis CJPRN-UMIN000002377Kanazawa university100
已完成
不适用
The combination therapy of PEG-IFN alpha 2b, Ribavirin and Telaprevir for the patients with chronic hepatitis C:the study for treatment duration by response guided therapy and prediction of efficacy by gene analysis in Japan.chronic hepatitis CJPRN-UMIN000018971agoya university500
招募中
不适用
Peg-IFN-alfa 2b/Ribavirin/Vaniprevir therapy for chronic hepatitis C: Effectiveness prediction by gene analysis and duration of therapychronic hepatitis CJPRN-UMIN000016639Kanazawa University100
招募中
不适用
Peg-IFN-alfa2b/Ribavirin/Telaprevir therapy for chronic hepatitis C: Effectiveness prediction by gene analysis and Duration of therapyJPRN-UMIN000008198Kanazawa University200